Journal of clinical gastroenterology
-
J. Clin. Gastroenterol. · Aug 2004
Randomized Controlled Trial Multicenter Study Comparative Study Clinical TrialParecoxib sodium demonstrates gastrointestinal safety comparable to placebo in healthy subjects.
The gastrointestinal safety of the novel injectable cyclooxygenase-2 selective inhibitor, parecoxib sodium, was compared with the nonselective nonsteroidal anti-inflammatory drug, ketorolac, and placebo in healthy subjects. ⋯ Parecoxib sodium 40 mg twice daily for 7 days has a gastrointestinal safety profile superior to ketorolac 30 mg 4 times daily for 5 days, and comparable to placebo.